Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). 1988

R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
National Cancer Institute, Bethesda, Maryland.

Five dose regimens of 2',3'-dideoxycytidine (ddC) were administered, intravenously for 2 weeks then orally for 4 or more weeks, to 20 patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC). ddC was well absorbed from the gut and crossed the blood-brain barrier. 10 of the 15 patients who received 0.03-0.09 mg/kg every 4 h had increases in their absolute number of T4+ T cells at week 2 (p less than 0.05), though in many these rises were not sustained. 11 of 13 evaluable patients had a fall in their serum human immunodeficiency virus (HIV)p24 antigen by week 2 of therapy (p less than 0.01); in 4 patients the p24 antigen subsequently rose to baseline while in others the decline was sustained. Dose-related toxic effects included cutaneous eruptions, fever, mouth sores, thrombocytopenia, and neutropenia. A reversible painful peripheral neuropathy developed in 10 patients after 6-14 weeks' treatment. These results suggest that ddC has activity against HIV in vivo and has a different toxicity profile from that of zidovudine (AZT). 6 patients with AIDS or ARC were given an alternating regimen of oral AZT (200 mg every 4 h for 7 days) and oral ddC (0.03 mg/kg every 4 h for 7 days). The regimen was well tolerated, and the 5 patients who completed 9 or more weeks of treatment had sustained rises in their T4+ T cells and/or falls in p24 antigen.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003841 Deoxycytidine A nucleoside component of DNA composed of CYTOSINE and DEOXYRIBOSE. Cytosine Deoxyribonucleoside,Cytosine Deoxyriboside,Deoxyribonucleoside, Cytosine,Deoxyriboside, Cytosine
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
November 1990, The Journal of pediatrics,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
January 1992, Annals of internal medicine,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
September 1996, Journal of virology,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
October 1993, The Journal of infectious diseases,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
November 1993, German journal of ophthalmology,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
December 1988, Medizinische Monatsschrift fur Pharmazeuten,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
May 1990, The American journal of medicine,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
April 1991, The Journal of infectious diseases,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
December 1989, Journal of the American Academy of Dermatology,
R Yarchoan, and C F Perno, and R V Thomas, and R W Klecker, and J P Allain, and R J Wills, and N McAtee, and M A Fischl, and R Dubinsky, and M C McNeely
June 1989, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!